The U.S. microfluidics market size was estimated at USD 13.11 billion in 2023 and is expected to be worth around USD 39.29 billion by 2033, poised to grow at a compound annual growth rate (CAGR) of 11.6% during the forecast period 2024 to 2033.
The demand for microfluidics devices is driven by their capacity to conserve rare samples and reduce reagent waste by analyzing small sample amounts. Cutting-edge technologies have been developed as a result of their growing application in research and diagnostics. The market has grown as a result of the expansion of applications for microfluidics-based lab equipment in pharmaceutical and biomedical research, as well as their compatibility with current research processes.
In 2023, the U.S. held a market share of about 39.2% in the global microfluidics industry. The market is expected to increase as a result of the increasing use of microfluidics devices in various research and diagnostic applications. For instance, there have been more microfluidic devices that are appropriate for treating eye-related disorders in the last ten years. The increase of uses of microfluidics technology in biomedical and pharmaceutical research has been largely attributed to the development of microfluidics-based lab equipment into more robust instruments that are compatible with established research procedures. It is anticipated that microfluidics will be employed in biological settings. Micro-scale procedures are carried out by experts in this field to guarantee better control, quicker outcomes, and reduced expenses at different phases of drug development.
The number of COVID-19 cases has surged, which has raised the need for microfluidics instruments. Widely accepted, PCR-based diagnostics are now the standard for COVID-19 diagnosis. Many manufacturers have boosted production and introduced new products in response to the pandemic in order to accommodate the growing demand for IVD tests. By combining microfluidics with PCR, testing can be accelerated and results can be obtained with high precision in less than ten minutes. For example, BeforCure, a spin-off of Elvesys, has created a quick PCR-on-chip virus detection method. This product, which is based on Fastgen technology, uses the advantages of microfluidics to deliver test results in less than 30 minutes.
The ability of microfluidics devices to evaluate small sample volumes is a major advantage. This helps preserve difficult-to-produce samples and reduces reagent waste. The need for low-volume sample devices has increased with the release of these devices. This need has been further spurred by a rise in research efforts by clinical and analytical researchers. Conventional genome analysis techniques are expensive and time-consuming since they require decoding the complete DNA. Because they can analyze small sample volumes, microfluidics devices have advantages like less waste from reagents and sample conservation. Since their introduction, the need for low-volume sample analysis has grown, as has their application in research.
Compared to conventional genome analysis techniques, these devices are more efficient since they require smaller sample volumes for data interpretation. They made it possible to reduce lab processes and replace them with lab-on-a-chip technologies. Recent product introductions, such as the low-volume online degassing modules from Biotech Fluidics that were introduced in July 2023, have boosted the market.
Microfluidics devices for ophthalmological diseases have grown increasingly accessible over the last ten years. They have effectively assessed vascular endothelium growth factor levels, detected infections, and measured glucose levels. Contact lens technology has been exploited in recent years to provide diagnostic and therapeutic options. Guan's group, for example, created a contact lens-on-a-chip for precision medical care. Among these developments is the analysis of small-volume nasal secretions for illness research.
A group from Loschmidt laboratories developed a microfluidic platform for efficient and rapid enzyme research in March 2021 in association with ETH Zurich. This cutting-edge technology is already being used to study the evolution of bioluminescent enzymes and create novel thrombolytics for the treatment of stroke. Additionally, in November 2019, IMT and Panasonic Corporation collaborated to create a glass molding technology for mass-producing microfluidic devices. Devices for biological, environmental, and medical analysis and sensing are made using this approach, which is more accurate and economical than conventional glass etching methods. It is anticipated that this will help the industry expand in the future.
| Report Attribute | Details |
| Market Size in 2024 | USD 14.63 Billion |
| Market Size by 2033 | USD 39.29 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 11.6% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Product, application, material type, technology |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Illumina, Inc.; F. Hoffmann-La Roche Ltd; PerkinElmer, Inc.; Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; Danaher Corporation; Abbott; Thermo Fisher Scientific; Standard BioTools |
Polydimethylsiloxane (PDMS) dominated the market and held the highest revenue market share of 35.89% in 2023 and is expected to grow at the fastest CAGR during the forecast period. PDMS, a polymer extensively used in microfluidics, offers numerous benefits such as non-toxicity, durability, optical clarity, gas and oxygen permeability, biocompatibility, elasticity, affordability, and the ability to create intricate microfluidic device designs by layering multiple levels. The swift uptake of microfluidics-enabled LOC devices has opened numerous growth avenues for PDMS in experimental microfluidics. Given its biocompatibility, permeability, and minimal autofluorescence, PDMS is projected to see substantial use in various future biotechnology and biomedical engineering applications.
Glass has the second-highest market revenue share in 2023 and is expected to witness lucrative growth during the forecast period. Glass is a preferred material in microfluidics due to its optical transparency, chemical inertness, and biocompatibility, making it suitable for various applications in the field. In addition, Glass offers excellent properties for microfluidic devices, such as low autofluorescence levels and high thermal stability, which are crucial for maintaining the integrity of samples and ensuring accurate results in microfluidic systems. These characteristics make Glass a popular choice in the microfluidics industry, contributing to its significant market revenue share.
Microfluidic components dominated the market with the largest revenue share of 70.14% during 2023 and are expected to grow at the highest CAGR during the forecast period. Based on microfluidic components, the market is segmented into chips, micro-pumps, sensors, and other components used in microfluidic devices. These components are small and offer flexibility in applications. These components support numerous instruments and technological applications, such as automation, screening, analysis, and quantitative determination of biological elements like galactose. The market demand for microfluidic components is predicted to rise in response to the increasing need for analyzing low-volume samples and the ongoing development of advanced technologies in this field. Droplet microfluidics, for example, has emerged as a powerful tool that enables fast and cost-effective compartmentalization of cells and analytes under precisely controlled conditions. This technology is highly robust and can facilitate high-throughput screening, further driving growth in the market during the projected period.
Microfluidic-based devices are anticipated to grow quickly during the forecast period. These devices leverage the principles of microfluidics to analyze fluids at the microscale level. They offer various advantages for biological analysis. Devices based on microfluidics require low reagent volume and smaller samples. These items are generally difficult to isolate when used in bulk quantities and are expensive. Hence, microfluidic-based devices reduce the significant cost of the entire laboratory analytical process. In addition, these devices are smaller, which saves space and allows the simultaneous processing of multiple analytes. Such benefits associated with these systems are expected to drive the microfluidic-based devices market.
Lab-on-a-chip dominated the market with the highest CAGR of 37.11% in 2023. This technology enables quick DNA probe sequencing and high-speed thermal shifts at the microscale for DNA amplification using PCR. Elveflow’s Fastgene system, the fastest qPCR system, can detect bacteria and viruses in just 7 minutes. Nanopore technologies promise faster genome sequencing of DNA probes than traditional lab-on-a-chip methods. They also offer the potential for quick immunoassays, which can be done in 10 seconds, significantly faster than macroscopic technologies. Lab-on-a-chip technology has shown potential in cell biology, particularly in regulating cells at the single-cell level while handling large volumes of cells quickly. Elveflow’s Opto Reader, a fast-optical detector, aids cell detection and isolation. The technology is also used in stem cell differentiation, micro patch-clamp, cell sorting, and high-speed flow cytometry. Thus, lab-on-a-chip technology holds great promise for ultra-fast detection of viruses and bacteria.
Organs-on-chips is anticipated to witness the fastest growth of CAGR of 14.7% from 2024 to 2033. They play a crucial role in the discovery and development of drugs. The National Center for Advancing Translational Science (NCATS), in collaboration with the FDA and other National Institute of Health (NIH) centers, has focused on drug discovery since 2012 through its Tissue Chip for Drug Screening initiative. This initiative involves creating human tissue chips that accurately represent human organs, aiming to bridge the gap between research discovery and clinical trials and focus on high-need cures. For example, in March 2022, NCATS collaborated with the U.S. The FDA and various NIH institutes are collaborating to create human tissue chips that closely resemble the structure and function of organs in the human body, including the heart, liver, and lungs. This effort aims to enhance the accuracy and speed of predicting human drug safety.
Medical dominated the market and held the highest revenue share of 81.69% in 2023 and is expected to grow at the fastest CAGR during the forecast period. Microfluidics, a key technology in biological analysis, chemical synthesis, and IT, has revolutionized conventional lab equipment. It allows minimal reagent use, maximum information from small samples, simplified assay protocols, improved sample processing, and precise control of cell microenvironments. Its benefits extend to medical and pharmaceutical applications, including infectious disease diagnosis, cancer treatment, and the creation of functional tissues and organs. For instance, in August 2022, a team in Atlanta developed the Cluster-Well chip using microfluidics to detect and treat metastatic cancer swiftly. In addition, the ability to automate the preparation of PCR reaction mix is a feature of microfluidic PCR devices. This automation significantly reduces the chances of false positives and contamination due to human error.
Non-medical segment is expected to grow lucratively during the forecast period. Microfluidics is used for crude oil extraction, plant pathogen detection, and gas bubble production in non-medical fields. It’s ideal for developing methods to extract crude oil from pollutant-mixed porous rocks due to its ability to handle complex interactions between pore structure and fluids. Gas bubbles, particularly micron-scale ones, are widely used in various industries, including food for fat reduction, texture tailoring, and other industries for producing active ingredients, mesoporous materials, and natural gas recovery. Generating micron-scale gas bubbles in the microfluidic industry offers new opportunities for highly controlled fluid compartmentalization.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Microfluidics market.
By Product
By Application
By Material Type
By Technology
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers